Journal article
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers The TARGET-TP Randomized Clinical Trial
Marliese Alexander, Sam Harris, Craig Underhill, Javier Torres Corredor, Sharad Sharma, Nora Lee, Huili Wong, Richard Eek, Michael Michael, Jeanne Tie, Jennifer Rogers, Alexander G Heriot, David Ball, Michael MacManus, Rory Wolfe, Benjamin J Solomon, Kate Burbury
JAMA Oncology | American Medical Association | Published : 2023
Abstract
Importance: Thromboprophylaxis for individuals receiving systemic anticancer therapies has proven to be effective. Potential to maximize benefits relies on improved risk-directed strategies, but existing risk models underperform in cohorts with lung and gastrointestinal cancers. Objective: To assess clinical benefits and safety of biomarker-driven thromboprophylaxis and to externally validate a biomarker thrombosis risk assessment model for individuals with lung and gastrointestinal cancers. Design, Setting, and Participants: This open-label, phase 3 randomized clinical trial (Targeted Thromboprophylaxis in Ambulatory Patients Receiving Anticancer Therapies [TARGET-TP]) conducted from June 2..
View full abstractGrants
Awarded by Victorian Cancer Agency
Awarded by Australian National Health and Medical Research Council
Funding Acknowledgements
This study was supported by the Peter MacCallum Cancer Foundation (fellowship to Dr Alexander), grant ECHSRF18006 from the Victorian Cancer Agency (Dr Alexander), and grant 1196211 from the Australian National Health and Medical Research Council (Dr Alexander).